TBC1D16 Activators
Forskolin, a diterpene, acts by raising intracellular cAMP levels, which activate protein kinase A and may indirectly modulate TBC1D16 through phosphorylation events. The macrolide rapamycin, in contrast, is a selective mTOR inhibitor, exerting its effect on the intricate mTOR signaling pathways, which could impact TBC1D16's role in cellular metabolism and growth processes. Small molecule inhibitors such as Y-27632 and SB203580 target the Rho-associated protein kinase and p38 MAP kinase, respectively, altering the cytoskeletal dynamics and stress response pathways, which may in turn affect TBC1D16's trafficking-related functions.
U0126 and PD98059, both of which act as MEK inhibitors, can modify the MAPK/ERK pathway, potentially influencing TBC1D16's activity or expression. LY294002 and Wortmannin, as PI3K inhibitors, impact the AKT signaling pathway, which is integral to membrane trafficking and could thereby influence TBC1D16's role within these cellular processes. Compounds like PP2, an Src family kinase inhibitor, and Go6976, a PKC inhibitor, may modulate signaling cascades, affecting TBC1D16's GAP activity for Rab GTPases or its interactions with other proteins. NSC23766 specifically inhibits Rac1, a small Rho GTPase, which can impact actin cytoskeleton remodeling, possibly influencing TBC1D16's involvement in intracellular transport.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular levels of cAMP, which can lead to the activation of PKA and potential subsequent phosphorylation events that may modulate TBC1D16. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and metabolism, which may impact TBC1D16 activity through altered cellular signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, affecting cytoskeletal organization. ROCK-mediated changes in cell morphology may influence TBC1D16's role in intracellular trafficking. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially affecting stress response pathways that could indirectly modify TBC1D16 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which may affect the ERK pathway and alter the phosphorylation state of proteins, potentially including TBC1D16. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, affecting the AKT signaling pathway and possibly influencing TBC1D16 activity through changes in membrane trafficking. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor, which may affect signaling cascades that modulate TBC1D16's GAP activity for Rab GTPases. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC23766 inhibits Rac1, which may impact actin cytoskeleton dynamics and potentially influence TBC1D16-related trafficking processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK, which may alter the MAPK/ERK pathway, potentially affecting TBC1D16's activity or expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, potentially modifying the cellular response to stress and indirectly affecting TBC1D16's function. | ||||||